Shares of Calithera Biosciences, Inc. (CALA, Financial) soared more than 35% in after-hours trading on Thursday, following the announcement of an exclusive global license agreement with TransTech Pharma, a clinical stage pharmaceutical company, granting CALA exclusive world-wide rights to research, develop and commercialize TransTech's portfolio of hexokinase II inhibitors.
Hexokinase II is the first enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks required for cancer cell growth.
According to CALA, this hexokinase II inhibitor program will further expand its portfolio of pre-clinical programs and solidify the company's leadership in the area of tumor metabolism drug research and development as CALA is now able to target two essential nutrients that cancer cells rely on for growth and survival: glutamine and glucose
The field of tumor metabolism seeks to exploit the unique ways in which cancer cells take up and utilize nutrients in order to grow and proliferate.
CALA is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
More about Calithera Biosciences, Inc. (CALA, Financial) at www.calithera.com
**
After the closing bell on Thursday, YY Inc. (YY, Financial) reported stronger-than-expected quarterly results, driven by the strength of its online music and entertainment business.
For the fourth quarter 2014, YY posted net revenues of RMB1,170.6 million ($188.7 million), a 91.2% increase year over year, and non-GAAP net income of RMB410.8 million ($66.2 million), or RMB6.74 ($1.04) per diluted ADS, compared to non-GAAP net income of RMB216.9 million, or RMB3.63 per diluted ADS in the same period the prior year, topping the Capital IQ Consensus Estimate of $0.85 earnings per share on revenues of $181.1 million for the period
YY's 2014 net revenues increased 101.7% from the previous year to RMB3,678.4 million ($592.8 million). YY has more than doubled its total revenues every single year for the past nine consecutive years.
According to its business outlook for the first quarter of 2015, YY expects its net revenues to be between RMB1.06 billion and RMB1.08 billion, representing a year-over-year growth of approximately 59% to 62%.
YY is a revolutionary real-time interactive social platform that engages users in real-time online group activities through voice, text and video.
More about YY Inc. (YY, Financial) at www.YY.com
**
Crown Equity Holdings Inc. (CRWE, Financial) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network (www.CRWE-PR.com), a growing network of community targeted sites.
It has recently included Hesperia, California (www.hesperia.crwe-pr.com) into the CRWE Network.
Hesperia is located in San Bernardino County, California, seated in the Mojave Desert 78 miles northeast of Los Angeles. The locals refer to the surrounding area as the High Desert.
The City of Hesperia had an estimated population in 2013 (U.S. Census Bureau) of 92,147, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE Network has reached the 1,487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal (www.BusinessDirectory.crwe-pr.com) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (CRWE, Financial) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
